United States
Print page content Print
Increase text size Decrease text size
Text Size

References

  1. Stegemann MR, Sherington J, Blanchflower S. Pharmacokinetics and pharmacodynamics of cefovecin in dogs. J Vet Pharmacol Ther. 2006;29(6):501-511.
  2. Stegemann MR, Sherington J, Coati N, Brown SA, Blanchflower S. Pharmacokinetics of cefovecin in cats. J Vet Pharmacol Ther. 2006;29(6):513-524.
  3. Six R, Cherni J, Chesebrough R, et al. Efficacy and safety of cefovecin in treating bacterial folliculitis, abscesses, or infected wounds in dogs. J Am Vet Med Assoc. 2008;233(3):433-439.
  4. Six R, Cleaver DM, Lindeman CJ, et al. Effectiveness and safety of cefovecin sodium, an extended-spectrum injectable cephalosporin, in the treatment of cats with abscesses and infected wounds. J Am Vet Med Assoc. 2009;234(1):81-87.
  5. Data on file, Convenia First to Use Program, 2008, Zoetis Inc.
  6. Wright AK, Fadok V, Amodie D. First treatment success with injectable cefovecin sodium in dogs for superficial pyoderma, wounds, and abscesses in different dog populations. Presented at: ISPPR 21st Annual International Meeting; May 21–25, 2016; Washington, DC.
  7. Speed of Response, prospective N=45, VCA general practice, acute moist dermatitis. 2014–2015. Data on file.
  8. Fujii T, Takatsu S, Stegemann M, Ogata M, Kamata S. Clinical efficacy and safety of an injectable formulation of cefovecin in the treatment of bacterial skin infections of dogs [in Japanese]. Jpn J Vet Dermatol. 2007;13(2):81-88.
  9. Stegemann MR, Coati N, Passmore CA, Sherington J. Clinical efficacy and safety of cefovecin in the treatment of canine pyoderma and wound infections. J Small Anim Pract. 2007;48(7):378-386.
  10. CONVENIA [prescribing information]. Kalamazoo, MI: Zoetis Inc.; 2013.
  11. Maddison JE. Medication compliance in small animal practice. Irish Vet J. 2011;6(3):1-5.
  12. AAHA Executive Summary of Compliance in Companion Animal Practices. 2002.
  13. Take as directed: a prescription not followed. National Community Pharmacists Association. http://www.ncpanet.org/pdf/adherence/patientadherence-pr1206.pdf. Accessed June 19, 2017.
  14. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
  15. Simplicef [package insert]. Kalamazoo, MI: Zoetis, Inc; 2013.
  16. Plumb DC. Veterinary Drug Handbook. 5th ed. Stockholm Widc.: PharmaVet; Ames, Iowa: Distributed by Blackwell Publishing, 2005: 145.
  17. Weese JS, Faires MC, Frank LA, et al. Factors associated with methicillin-resistant versus methicillin-susceptible Staphylococcus pseudintermedius infection in dogs. J Am Vet Med Assoc. 2012;240(12):1450-1455. doi:10.2460/javma.240.12.1450
  18. Eckholm NG, Outerbridge CA, White SD, et al. Prevalence of and risk factors for isolation of meticillin-resistant Staphylococcus spp. from dogs with pyoderma in northern California, USA. Vet Dermatol. 2013;24(1):154-161. doi:0.1111/j.1365-3164.2012.01051.x
  19. Nienhof U, Kadlec K, Chaberny IF, et al. Methicillin-resistant Staphylococcus pseudintermedius among dogs admitted to a small animal hospital. Vet Micro. 2011;150:191-197. doi:10.1016/j.vetmic.2010.12.018
  20. Bergström A, Gustafsson C, Leander M, et al. Occurrence of methicillin-resistant Staphylococci in surgically treated dogs and the environment in a Swedish animal hospital. J Small Anim Pract. 2012;53(7):404-410. doi:10.1111/j.1748-5827.2012.01238.x
  21. Lehner G, Linek M, Bond R, et al. Case-control risk factor study of methicillin-resistant Staphylococcus pseudintermedius (MRSP) in dogs and cats in Germany. Vet Microbiol. 2014;168(1):154-160. doi:10.1016/j.vetmic.2013.10.023
  22. Beck KM, Waisglass SE, Dick HL, et al. Prevalence of meticillin-resistant Staphylococcus pseudintermedius (MRSP) from skin and carriage sites of dogs after treatment of their meticillin-resistant or meticillin-sensitive staphylococcal pyoderma. Vet Dermatol. 2012;23(4):369-375. doi:10.1111/j.1365-3164.2012.01035.x
  23. Hensel N, Zabel S, Hensel P. Prior antibacterial drug exposure in dogs with meticillin-resistant Staphylococcus pseudintermedius (MRSP) pyoderma. Vet Dermatol. 2016 Apr;27(2):72-8e20. doi:10.1111/vde.12292
  24. Boothe DM, Debavalya N. Impact of routine antimicrobial therapy on canine fecal Escherichia coli antimicrobial resistance: a pilot study. Intern J Appl Res Vet Med. 2011;9(4):396-406.
  25. Grønvold AM, L’abée-Lund TM, Sørum H, et al. Changes in fecal microbiota of healthy dogs administered amoxicillin. FEMS Microbiol Ecol. 2010;71(2):313-326. doi:10.1111/j.1574-6941.2009.00808.x
  26. Trott DJ, Filippich LJ, Bensink JC, et al. Canine model for investigating the impact of oral enrofloxacin on commensal coliforms and colonization with multidrug-resistant Escherichia coli. J Med Microbiol. 2004;53:439-443.
  27. Gibson JS, Morton JM, Cobbold RN, et al. Risk factors for multidrug-resistant Escherichia coli rectal colonization of dogs on admission to a veterinary hospital. Epidemiol Infect. 2011;139(2):197-205. doi:10.1017/S0950268810000798
  28. Gibson JS, Morton JM, Cobbold RN, et al. Risk factors for dogs becoming rectal carriers of multidrug-resistant Escherichia coli during hospitalization. Epidemiol Infect. 2011;139(10):1511-1521. doi:10.1017/S095026881000278
  29. Moreno A, Bello H, Guggiana D, et al. Exended-spectrum β-lactamases belonging to CTX-M group produced by Escherichia coli strains isolated from companion animals treated with enrofloxacin. Vet Micro. 2008;129(1-2):203-208. doi:10.1016/j.vetmic.2007.11.011
  30. Damborg P, Gaustad IB, Olsen JE, et al. Selection of CMY-2 producing Escherichia coli in the faecal flora of dogs treated with cephalexin. Vet Microbiol. 2011;151(3-4):404-408. doi:10.1016/j.vetmic.2011.03.015
  31. Schmidt V, Snoop S, Dawson S, et al. British Small Animal Veterinary Association 2014 Congress proceedings; April 3–6, 2014; Birmingham, UK.
Cat and Dog image

Zoetis supports the responsible use of antibiotics in animals and people.
Learn about our commitment to antibiotic stewardship »

IMPORTANT SAFETY INFORMATION: People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to CONVENIA. Do not use in dogs or cats with a history of allergic reactions to penicillins or cephalosporins. Side effects for both dogs and cats include vomiting, diarrhea, decreased appetite/anorexia and lethargy. See full Prescribing Information.